Paid Clinical Trials and Focus Groups by Category |
|
|
|
Conditions: Bladder Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter; Urethral Cancer
Interventions: Drug: cisplatin; Drug: gemcitabine hydrochloride; Drug: sunitinib malate
Sponsor: Wales Cancer Trials Unit
Recruiting - verified March 2010
Conditions: Bladder Cancer; Cervical Cancer; Colorectal Cancer; Endometrial Cancer; Gastrointestinal Complications; Long-term Effects Secondary to Cancer Therapy in Adults; Ovarian Cancer; Prostate Cancer; Radiation Toxicity; Sarcoma; Testicular Germ Cell Tumor; Vaginal Cancer
Interventions: Other: questionnaire administration; Procedure: gastrointestinal complications management/prevention; Procedure: quality-of-life assessment
Sponsor: Royal Marsden NHS Foundation Trust
Recruiting - verified March 2010
Conditions: Advanced Gastric Cancer; Gastro-esophageal Junction Cancer
Interventions: Drug: AUY922; Drug: Docetaxel or Irinotecan
Sponsor: Novartis Pharmaceuticals
Not yet recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: systemic chemotherapy; Procedure: adjuvant therapy; Procedure: quality-of-life assessment; Procedure: therapeutic conventional surgery
Sponsor: University College London Hospitals
Recruiting - verified March 2010
Condition: Ovarian Cancer
Interventions: Drug: olaparib; Drug: paclitaxel; Drug: carboplatin
Sponsor: AstraZeneca
Recruiting - verified March 2010
Conditions: Fallopian Tube Cancer; Ovarian Cancer
Interventions: Biological: bevacizumab; Drug: capecitabine; Drug: carboplatin; Drug: oxaliplatin; Drug: paclitaxel; Procedure: quality-of-life assessment
Sponsor: University College London Hospitals
Recruiting - verified March 2010
Condition: Breast Cancer Mortality
Intervention: Other: Invitation for breast screening
Sponsors: University of Oxford; Department of Health, United Kingdom
Not yet recruiting - verified March 2010
Condition: Colorectal Cancer
Intervention:
Sponsors: Newcastle University; Northumbria Healthcare NHS Foundation Trust
Recruiting - verified February 2010
Conditions: Leukemia; Mucositis; Oral Complications
Interventions: Biological: epratuzumab; Biological: palifermin; Biological: rituximab; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: fludarabine phosphate; Drug: imatinib mesylate; Drug: melphalan; Drug: mercaptopurine; Drug: methotrexate; Drug: nelarabine; Drug: pegaspargase; Drug: vincristine sulfate; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: assessment of therapy complications; Radiation: total-body irradiation
Sponsor: University College London Hospitals
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Intervention:
Sponsor: Sanofi-Aventis
Recruiting - verified February 2010
Condition: Pilonidal Sinus
Intervention:
Sponsor: ConvaTec Inc.
Completed - verified March 2010
Conditions: Breast Cancer; Bone Metastases
Intervention: Drug: Radium-223 chloride (Alpharadin)
Sponsor: Algeta ASA
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: Eicosapentaenoic acid free fatty acid; Drug: Placebo
Sponsor: University of Leeds
Not yet recruiting - verified February 2010
Condition: Multiple Myeloma
Intervention: Drug: KW-2478 and bortezomib
Sponsors: Kyowa Hakko Kirin Pharma, Inc.; Kyowa Hakko Kirin UK, Ltd.; Kyowa Hakko Kirin Company, Limited
Not yet recruiting - verified January 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Not yet recruiting - verified January 2010
Condition: Head and Neck Neoplasms
Interventions: Drug: Pemetrexed; Drug: Cetuximab; Drug: Cisplatin
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Intervention: Biological: anti-EGFr Monoclonal Antibody (Zalutumumab) for infusion
Sponsor: Genmab
Recruiting - verified March 2010
Condition: Gastric Cancer
Interventions: Drug: trastuzumab; Drug: fluorouracil; Drug: cisplatin; Drug: capecitabine
Sponsors: Hoffmann-La Roche; Chugai Pharmaceutical
Active, not recruiting - verified February 2010
Condition: Skin Cancer
Interventions: Dietary Supplement: Omega-3 PUFA; Dietary Supplement: Gelatine
Sponsor: University of Manchester
Recruiting - verified March 2010
Conditions: Barrett Syndrome; Barrett's Syndrome; Barrett's Esophagus; Barrett Esophagus; Adenocarcinoma
Interventions: Device: Standard endoscopic treatment of BE; Device: pCLE guided endoscopic treatment of BE
Sponsors: Mauna Kea Technologies; Cellvizio Inc.
Recruiting - verified March 2010
Condition: Carcinoma, Renal Cell
Interventions: Drug: BIBF 1120; Drug: sunitinib
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Locally Advanced or Metastatic Solid Tumors
Intervention: Drug: MK2206 plus AZD6244
Sponsors: Merck; AstraZeneca
Recruiting - verified March 2010
Conditions: Ovarian Neoplasms; Peritoneal Neoplasms
Interventions: Drug: Placebo; Drug: BIBF 1120
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Head and Neck Cancer
Interventions: Drug: RO5083945; Drug: cetuximab
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Lymphocytic Leukemia, Chronic
Interventions: Drug: RO5072759; Drug: rituximab; Drug: chlorambucil
Sponsors: Hoffmann-La Roche; Genentech
Recruiting - verified February 2010
Condition: Advanced Solid Tumors
Interventions: Drug: PF-01367338; Drug: Carboplatin; Drug: PF-01367338; Drug: Carboplatin; Drug: Paclitaxel; Drug: PF-01367338; Drug: Cisplatin; Drug: Pemetrexed
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Malignant Melanoma
Interventions: Drug: RO5185426; Drug: dacarbazine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Melanoma
Interventions: Drug: Tasisulam; Drug: Paclitaxel
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Prostate Cancer
Intervention: Drug: CNTO888
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Condition: Colorectal Cancer
Interventions: Drug: CS-7017; Drug: Placebo
Sponsor: Daiichi Sankyo Inc.
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: BIBF 1120; Drug: BIBF 1120; Drug: Sorafenib; Drug: Sorafenib
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Thyroid Neoplasm
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified March 2010
Condition: Cancer
Interventions: Biological: adoptive immunotherapy; Biological: alemtuzumab; Biological: in vitro-treated peripheral blood lymphocyte therapy; Drug: foscarnet sodium; Drug: ganciclovir; Genetic: polymerase chain reaction; Procedure: allogeneic hematopoietic stem cell transplantation; Procedure: infection prophylaxis and management; Procedure: peripheral blood stem cell transplantation; Procedure: standard follow-up care; Radiation: radiation therapy
Sponsor: University Hospital Birmingham
Recruiting - verified September 2009
Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: pertuzumab; Drug: trastuzumab [Herceptin]; Drug: trastuzumab [Herceptin]; Drug: docetaxel; Drug: docetaxel; Drug: FEC: 5-Fluorouracil/epirubicin/cyclophosphamide; Drug: carboplatin; Drug: trastuzumab
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Colorectal Cancer
Interventions: Biological: bevacizumab; Biological: cetuximab; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium; Drug: oxaliplatin; Genetic: RNA analysis; Genetic: cytogenetic analysis; Genetic: fluorescence in situ hybridization; Genetic: gene expression analysis; Genetic: mutation analysis; Genetic: protein expression analysis; Other: diagnostic laboratory biomarker analysis; Other: immunohistochemistry staining method; Other: questionnaire administration; Procedure: cognitive assessment
Sponsor: Medical Research Council
Recruiting - verified February 2010
Conditions: Cancer; Advanced Solid Malignancies
Intervention: Drug: AZD4547
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Glioblastoma
Interventions: Procedure: Radiotherapy; Procedure: Radiotherapy; Drug: BIBW2992; Drug: BIBW2992; Drug: Temozolomide
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Imatinib
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified January 2010
Condition: Castration-Resistant Prostate Cancer
Interventions: Drug: MDV3100; Drug: Placebo
Sponsor: Medivation, Inc.
Recruiting - verified March 2010
Conditions: Chronic Myeloproliferative Disorders; Leukemia; Lymphoma; Lymphoproliferative Disorder; Multiple Myeloma and Plasma Cell Neoplasm; Myelodysplastic Syndromes; Myelodysplastic/Myeloproliferative Diseases
Interventions: Drug: cyclophosphamide; Drug: cyclosporine; Drug: fludarabine phosphate; Drug: mycophenolate mofetil; Other: laboratory biomarker analysis; Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation; Procedure: umbilical cord blood transplantation; Radiation: total-body irradiation
Sponsor: Cancer Research UK
Recruiting - verified August 2009
Conditions: Myeloid Leukemia; Lymphoblastic Leukemia; Lymphoma; Multiple Myeloma; Myelodysplastic Syndrome; Myeloproliferative Disorders
Intervention: Biological: Donor lymphocyte preparation depleted of functional alloreactive T-cells
Sponsor: Kiadis Pharma
Recruiting - verified March 2010
Conditions: Bone Metastases in Men With Hormone-Refractory Prostate Cancer; Bone Metastases in Subjects With Advanced Breast Cancer; Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Intervention: Drug: amg 162
Sponsor: Amgen
Enrolling by invitation - verified March 2010
Condition: Breast Neoplasms
Interventions: Drug: BIBW 2992; Drug: Herceptin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Arthritis, Rheumatoid
Interventions: Drug: CP-690,550; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550; Drug: Placebo; Drug: CP-690,550
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: HPV Infections
Interventions: Biological: Cervarix; Biological: Gardasil
Sponsor: Health Protection Agency
Recruiting - verified August 2009
Conditions: Carcinoma, Non-Small-Cell Lung; Adenocarcinoma
Interventions: Drug: BIBW 2992; Drug: BIBW 2992; Drug: Cisplatin; Drug: Cisplatin; Drug: Pemetrexed; Drug: Pemetrexed
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Acute Myeloid Leukemia
Interventions: Drug: AZD1152; Drug: LDAC; Drug: AZD1152 + LDAC
Sponsor: AstraZeneca
Recruiting - verified March 2010
Condition: Glioblastoma
Interventions: Drug: Dasatinib; Drug: Lomustine
Sponsors: Bristol-Myers Squibb; European Organization for Research and Treatment of Cancer
Recruiting - verified December 2009
Condition: Tumors
Intervention: Drug: PKI-587
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Melanoma
Interventions: Drug: AZD2644; Drug: Dacarbazine
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Condition: HER2 Positive Breast Cancer
Interventions: Drug: docetaxel; Drug: trastuzumab-DM1 (T-DM1)
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Ovarian Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: paclitaxel; Drug: carboplatin
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Human Papillomavirus (HPV) Type 16/18 Infections; Cervical Neoplasia
Intervention: Procedure: Gynaecological follow-up
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Advanced Non-hematologic Malignancies
Intervention: Drug: PF-04605412
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib + Paclitaxel; Drug: Trastuzumab + Paclitaxel
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Multiple Myeloma
Interventions: Drug: Lenalidomide; Drug: bortezomib; Drug: Cyclophosphamide; Drug: bortezomib; Drug: Dexamethasone; Drug: Dexamethasone; Drug: bortezomib; Drug: Dexamethasone
Sponsor: Janssen-Cilag International NV
Recruiting - verified February 2010
Condition: B-Cell Chronic Lymphocytic Leukemia (B-CLL)
Interventions: Drug: Lenalidomide; Drug: Chlorambucil
Sponsor: Celgene Corporation
Recruiting - verified February 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006); Drug: Sorafenib (Nexavar, BAY43-9006) + Erlotinib, Tarceva
Sponsors: Bayer; Onyx Pharmaceuticals; OSI Pharmaceuticals; Hoffmann-La Roche
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Contrast-enhanced ultrasound guided biopsy; Procedure: ultrasound guided systematic biopsy
Sponsors: Bracco Diagnostics, Inc; Bracco Imaging SpA
Recruiting - verified February 2010
Condition: Chronic Myeloid Leukemia
Intervention: Drug: Dasatinib (Sprycel)
Sponsors: European Group for Blood and Marrow Transplantation; Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Drug: Ixabepilone; Drug: Doxorubicin; Drug: Paclitaxel
Sponsor: Bristol-Myers Squibb
Recruiting - verified March 2010
Condition: Solid Tumor
Interventions: Drug: ABT-263; Drug: Docetaxel
Sponsors: Abbott; Genentech
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: neratinib; Other: placebo
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Neoplasms
Intervention: Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Metastatic Non-Small Cell Lung Cancer; Lung Cancer, Non-Small Cell
Interventions: Drug: pazopanib and pemetrexed; Drug: pemetrexed and cisplatin
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: Ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Bladder Cancer
Interventions: Procedure: therapeutic conventional surgery; Radiation: radiation therapy
Sponsor: Institute of Cancer Research, United Kingdom
Active, not recruiting - verified March 2009
Conditions: Lymphoma, B-Cell; Lymphoma, Diffuse
Interventions: Drug: inotuzumab ozogamicin (CMC-544); Drug: rituximab
Sponsor: Wyeth
Recruiting - verified March 2010
Condition: Hepato Cellular Carcinoma (HCC)
Interventions: Drug: Brivanib; Drug: Placebo; Drug: Sorafenib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified November 2009
Conditions: Non-small Cell Lung Cancer; Anemia; Cancer; Lung Cancer
Interventions: Drug: darbepoetin alfa 500 mcg Q3W; Drug: placebo
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Lymphoma, Large-Cell, Anaplastic; Lymphoma, Non-Hodgkin
Intervention: Drug: SGN-35
Sponsor: Seattle Genetics, Inc.
Recruiting - verified February 2010
Conditions: Colorectal Neoplasms; Neoplasm Metastasis
Interventions: Drug: aflibercept (AVE0005); Drug: oxaliplatin; Drug: 5-FU; Drug: Folinic Acid
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer (NSCLC)
Interventions: Drug: Paclitaxel; Drug: Carboplatin; Drug: CT-322; Drug: Bevacizumab; Drug: Bevacizumab placebo (ie saline solution)
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Ovarian Cancer
Interventions: Drug: MORAb-003 (farletuzumab); Drug: MORAb-003 (farletuzumab); Drug: 0.9% Saline
Sponsor: Morphotek
Recruiting - verified October 2009
Condition: Locally Advanced, Metastatic Solid Tumors
Interventions: Drug: MK2206 combined with carboplatin + paclitaxel; Drug: MK2206 combined with docetaxel.; Drug: MK2206 combined with Erlotinib
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Ovarian Neoplasms; Pancreatic Neoplasms; Colorectal Neoplasms; Head and Neck Neoplasms; Lung Neoplasms
Intervention: Drug: CNTO 328; Anti-interleukin-6 monoclonal antibody
Sponsor: Centocor, Inc.
Recruiting - verified February 2010
Conditions: Metastatic; Colorectal Cancer
Interventions: Drug: Sorafenib (Nexavar, BAY43-9006) + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin); Drug: Matching placebo + mFOLFOX6 (5-FU, levo-leucovorin, oxaliplatin)
Sponsors: Bayer; Onyx Pharmaceuticals
Recruiting - verified February 2010
Conditions: Lymphoma (Non-Hodgkin's Lymphoma); Hodgkin's Disease or Multiple Myeloma; Front Line Mobilization; Transplantation
Intervention: Drug: Generic = Plerixafor
Sponsor: Genzyme
Active, not recruiting - verified March 2010
Conditions: Malignant Mesothelioma; Metastatic Cancer
Interventions: Other: talc; Procedure: therapeutic thoracoscopy; Procedure: therapeutic videothoracoscopy
Sponsor: Papworth Hospital
Recruiting - verified June 2009
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: RO5072759; Drug: RO5072759; Drug: CHOP(cyclophosphamide,doxorubicin,vincristine,prednisone); Drug: FC(fludarabine,cyclophosphamide)
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine; Drug: trastuzumab; Drug: lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Solid Tumors
Intervention: Drug: AG-013736
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: OFC Infusion; Drug: FC infusion
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Neoplasms
Interventions: Drug: BIBW2992; Drug: BIBW 2992; Drug: BIBW 2992; Drug: BIBW 2992; Drug: Paclitaxel; Drug: Paclitaxel; Drug: Paclitaxel; Drug: Bevacizumab; Drug: Carboplatin; Drug: Carboplatin
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: BIBF 1120 plus docetaxel; Drug: placebo plus docetaxel
Sponsor: Boehringer Ingelheim Pharmaceuticals
Recruiting - verified March 2010
Conditions: Skin Cancer; Melanoma; Metastatic Melanoma
Interventions: Drug: temozolomide; Drug: ABT-888; Drug: Placebo
Sponsor: Abbott
Active, not recruiting - verified March 2010
Condition: Solid Tumors
Intervention: Drug: Sunitinib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Renal Cell Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: interferon alfa-2a
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Placebo; Drug: Pemetrexed; Other: Best Supportive Care
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Conditions: Soft Tissue Sarcomas; Translocation-Related Sarcomas (TRS)
Intervention: Drug: Trabectedin, ET 743 and Yondelis
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; PharmaMar
Recruiting - verified February 2010
Condition: Gastrointestinal Stromal Tumor (GIST)
Interventions: Drug: Nilotinib (AMN107); Drug: imatinib (STI571)
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Conditions: Tuberous Sclerosis; Subependymal Giant Cell Astrocytoma
Interventions: Drug: Everolimus (RAD001); Other: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified February 2010
Condition: Urothelial Cancer
Intervention: Drug: TKI258
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Tuberous Sclerosis
Interventions: Drug: RAD001 (Everolimus); Drug: Placebo
Sponsor: Novartis Pharmaceuticals
Recruiting - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Oxaliplatin; Drug: Leucovorin; Drug: 5-FU; Drug: 5-FU; Drug: Leucovorin; Drug: 5-FU; Drug: Irinotecan
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Colon Cancer; Colorectal Cancer; Gastrointestinal Cancer; Metastatic Colorectal Cancer; Rectal Cancer
Interventions: Drug: Panitumumab + AMG 102; Drug: Panitumumab + AMG 479; Drug: AMG 479; Drug: AMG 102; Drug: Panitumumab
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Solid Tumors
Interventions: Drug: AZD2281; Drug: AZD2281; Drug: AZD2281; Drug: AZD2281; Drug: AZD2281; Drug: AZD2281
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: cisplatin; Drug: etoposide
Sponsor: Hoffmann-La Roche
Completed - verified February 2010
Conditions: Lung Cancer; Small Cell Lung Cancer; Solid Tumors; Extensive-Stage Small Cell Lung Cancer
Interventions: Drug: AMG 102 in combination with Cisplatin/Etopiside; Drug: AMG 479 in combination with Carboplatin/Etopiside; Drug: AMG 102 in combination with Carboplatin/Etopiside; Drug: AMG 479 in combination with Cisplatin/Etopiside
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Advanced Breast Cancer; Breast Cancer
Interventions: Drug: Neratinib; Drug: Lapatinib plus Capecitabine
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: ridaforolimus (MK8669); Drug: Comparator: Placebo; Drug: open-label ridaforolimus (MK8669)
Sponsors: Merck; Ariad Pharmaceuticals
Recruiting - verified March 2010
Condition: Leukemia
Interventions: Drug: Dasatinib; Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: axitinib; Drug: axitinib; Drug: chemotherapy; Drug: axitinib; Drug: chemotherapy
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Exemestane + Dasatinib; Drug: Exemestane + Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Erlotinib; Drug: PF-00299804
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Melanoma
Interventions: Biological: OncoVEXGM-CSF; Biological: GM-CSF
Sponsor: BioVex Limited
Recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: RG1507; Drug: Placebo; Drug: RG1507; Drug: Placebo; Drug: erlotinib [Tarceva]
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Ovarian Cancer
Interventions: Drug: AZD2281; Drug: matching placebo
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Conditions: Bladder Cancer; Brain and Central Nervous System Tumors; Esophageal Cancer; Intraocular Melanoma; Kidney Cancer; Lymphoma; Melanoma (Skin); Pancreatic Cancer; Transitional Cell Cancer of the Renal Pelvis and Ureter
Interventions: Genetic: DNA analysis; Genetic: polymorphism analysis; Other: laboratory biomarker analysis; Other: questionnaire administration
Sponsor: Cancer Research UK
Recruiting - verified September 2008
Conditions: Prostate Cancer; Ovarian Cancer
Interventions: Drug: Sagopilone 16 mg/m2 i.v., Acetyl-L-Carnitine (ALC) 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid; Drug: Sagopilone 16 mg/m2 i.v. and placebo 1000 mg tid, HRPC only: Prednisone or Prednisolone 5 mg bid
Sponsor: Bayer
Active, not recruiting - verified February 2010
Condition: Soft Tissue Sarcoma
Intervention: Drug: PAZOPANIB
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: placebo + docetaxel/prednisone; Drug: dasatinib + docetaxel/prednisone
Sponsor: Bristol-Myers Squibb
Recruiting - verified October 2009
Conditions: Solid Tumors; Ovarian Neoplasms; Prostate Cancer
Interventions: Drug: Comparator: MK4827 (PARP inhibitor); Drug: Comparator: MK4827 (PARP Inhibitor)
Sponsor: Merck
Recruiting - verified March 2010
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ofatumumab (GSK1841157) infusion; Drug: chlorambucil, tablets
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Biological: IMC-1121B; Drug: Paclitaxel; Drug: Carboplatin
Sponsor: ImClone LLC
Recruiting - verified February 2010
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: Comparator: erlotinib + dalotuzumab; Drug: Comparator: erlotinib monotherapy
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Esophagogastric Junction Adenocarcinoma; Gastric Cancer; Esophageal Cancer
Interventions: Drug: Capecitabine; Drug: Epirubicin; Drug: AMG 102; Drug: Cisplatin
Sponsor: Amgen
Recruiting - verified March 2010
Conditions: Chemotherapeutic Agent Toxicity; Lymphoma; Mucositis; Neurotoxicity
Interventions: Drug: glucarpidase; Drug: leucovorin calcium; Drug: methotrexate; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment; Radiation: radiation therapy
Sponsor: Cancer Research UK
Recruiting - verified November 2008
Condition: Locally Advanced and/or Metastatic Renal Cell Carcinoma
Interventions: Drug: Sunitinib; Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Carcinoma, Renal Cell; Adenocarcinoma, Renal Cell; Nephroid Carcinoma; Carcinoma, Hypernephroid
Interventions: Drug: bevacizumab, RAD001(Everolimus); Drug: bevacizumab, interferon alfa-2a
Sponsors: Novartis Pharmaceuticals; Roche Pharma AG
Recruiting - verified March 2010
Condition: Secondary Acute Myeloid Leukemia (Secondary AML, sAML)
Interventions: Drug: Daunorubicin and Cytarabine; Drug: Amonafide and Cytarabine
Sponsor: Antisoma Research
Recruiting - verified March 2010
Condition: Thyroid Cancer
Interventions: Drug: XL184; Drug: Placebo
Sponsor: Exelixis
Recruiting - verified March 2010
Conditions: Hormone Refractory Prostate Cancer; Bone Metastases
Interventions: Drug: Alpharadin (Radium-223); Drug: Placebo
Sponsor: Algeta ASA
Recruiting - verified March 2009
Condition: Non-small Cell Lung Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Carboplatin-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: sunitinib malate; Drug: sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Carcinoma, Hepatocellular
Interventions: Drug: Nexavar (Sorafenib, BAY43-9006); Drug: Placebo
Sponsor: Bayer
Recruiting - verified March 2010
Condition: Solid Tumor
Intervention: Drug: CHR-3996
Sponsor: Chroma Therapeutics
Recruiting - verified March 2010
Condition: Non Small Cell Lung Cancer
Interventions: Drug: Pemetrexed; Drug: Cisplatin; Drug: Etoposide; Drug: Cisplatin; Drug: Vinorelbine; Drug: Paclitaxel; Drug: Carboplatin; Radiation: Thoracic Radiation Therapy (TRT); Radiation: Thoracic Radiation Therapy (TRT)
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention:
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Condition: Kidney Neoplasms
Interventions: Drug: Axitinib (AG-013736); Drug: Sorafenib
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: Prednisone; Drug: sunitinib; Drug: Placebo; Drug: Prednisone
Sponsor: Pfizer
Recruiting - verified March 2010
Conditions: Prevention of Venous Thromboembolism; Cancer
Interventions: Drug: AVE5026; Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Conditions: Lymphoma; Neoplasms
Intervention: Drug: JNJ-26481585
Sponsors: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.; Janssen Pharmaceutica N.V., Belgium
Recruiting - verified February 2010
Conditions: Carcinoma, Large Cell; Carcinoma, Non-Small-Cell Lung; Carcinoma, Squamous Cell; Carcinoma, Adenosquamous Cell
Interventions: Drug: CP 751,871 (Figitumumab) and Erlotinib; Drug: Erlotinib
Sponsor: Pfizer
Terminated - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: placebo
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: trastuzumab; Drug: docetaxel; Drug: lapatinib ditosylate; Drug: paclitaxel; Other: immunohistochemistry staining method; Other: laboratory biomarker analysis; Procedure: quality-of-life assessment
Sponsors: NCIC Clinical Trials Group; GlaxoSmithKline
Recruiting - verified July 2009
Condition: Sarcoma
Interventions: Drug: AVE8062; Drug: Placebo
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Conditions: Locally Advanced Tumors; Metastatic Solid Tumors; Cancer; Neoplasms
Interventions: Drug: Comparator: MK2206; Drug: Comparator: MK2206
Sponsor: Merck
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: placebo; Drug: BIBW 2992
Sponsor: Boehringer Ingelheim Pharmaceuticals
Active, not recruiting - verified March 2010
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: erlotinib [Tarceva]; Drug: gemcitabine
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Sarcoma
Interventions: Drug: bevacizumab [Avastin]; Drug: Standard chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Sarcoma
Intervention: Drug: RG1507
Sponsors: Hoffmann-La Roche; Sarcoma Alliance for Research through Collaboration
Active, not recruiting - verified February 2010
Conditions: Advanced Non-Small Cell Lung Cancer; Transitional Cell Carcinoma; Soft Tissue Sarcoma; Gastric/Esophageal Adenocarcinoma; Pancreatic Cancer Including Ampulla of Vater
Interventions: Drug: brivanib; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: High Risk Stage III Melanoma
Interventions: Drug: ipilimumab; Drug: Placebo
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Condition: Ovarian Neoplasms
Interventions: Drug: AZD2281; Drug: Liposomal Doxorubicin; Drug: AZD2281
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Conditions: Breast Cancer; Breast Tumors; Metastatic Cancer
Interventions: Drug: AMG 479 or placebo administered with either exemestane or fulvestrant; Drug: AMG 479 or placebo administered with either exemestane or fulvestrant; Drug: AMG 479 or placebo administered with either exemestane or fulvestrant
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Neoplasms
Intervention: Drug: Sorafenib (Nexavar, BAY43-9006)
Sponsors: Bayer; ICON Clinical Research
Recruiting - verified March 2010
Condition: Hematologic Neoplasms
Intervention: Drug: RG7112
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Severe Caner Pain
Intervention: Drug: Oxycodone Hydrochloride
Sponsor: Mundipharma Research Limited
Terminated - verified March 2010
Condition: Carcinoma, Renal Cell
Intervention: Drug: Nexavar (Sorafenib, BAY43-9006)
Sponsor: Bayer
Active, not recruiting - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: Docetaxel; Drug: ZD4054
Sponsor: AstraZeneca
Recruiting - verified February 2010
Conditions: MDS; Myelodysplastic Syndromes; Thrombocytopenia
Interventions: Drug: Placebo; Biological: Romiplostim
Sponsor: Amgen
Recruiting - verified March 2010
Condition: Metastatic Colorectal Cancer
Interventions: Drug: Comparator: dalotuzumab (MK0646); Drug: Comparator: irinotecan hydrochloride; Drug: Comparator: cetuximab; Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Osteosarcoma; Sarcoma, Ewing's; Peripheral Neuroectodermal Tumor
Interventions: Drug: SCH 717454 (19D12); Drug: SCH 717454 (19D12)
Sponsor: Schering-Plough
Recruiting - verified March 2010
Conditions: Non-Small-Cell Lung Carcinoma; Adenocarcinoma
Interventions: Drug: Bevacizumab + Carboplatin + Paclitaxel; Drug: AG-013736 (axitinib) + Carboplatin + Paclitaxel
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Carcinoma, Non-Small Cell Lung Cancer
Intervention: Radiation: Comparator: CT or MRI and FDG-PET
Sponsor: Merck
Recruiting - verified March 2010
Conditions: Colorectal Neoplasms; Neoplasm Metastasis
Interventions: Drug: Aflibercept (AVE0005); Drug: Placebo
Sponsors: Sanofi-Aventis; Regeneron Pharmaceuticals; National Surgical Adjuvant Breast and Bowel Project (NSABP)
Recruiting - verified March 2010
Condition: Colorectal Neoplasm
Intervention: Biological: CP-751, 871
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Ewing's Sarcoma Family of Tumors
Intervention: Drug: CP-751,871
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Prostate Cancer After a Radical Treatment
Interventions: Drug: Avodart; Other: placebo
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
Conditions: Breast Cancer; Prostate Cancer; Bone Neoplasms
Interventions: Drug: AZD0530; Drug: Zoledronic Acid; Drug: Calcium; Drug: Vitamin D
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Condition: Inflammatory Breast Cancer
Interventions: Drug: lapatinib (Tykerb); Drug: pazopanib (GW786034); Drug: Pazopanib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Conditions: Early Breast Cancer; ErbB2+
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsor: GlaxoSmithKline
Active, not recruiting - verified February 2010
Condition: Non-Small-Cell Lung Cancer
Interventions: Drug: Drug: pemetrexed; Drug: Drug: erlotinib
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Bladder Cancer
Interventions: Procedure: quality-of-life assessment; Procedure: questionnaire administration
Sponsor: University of Birmingham
Recruiting - verified February 2010
Conditions: Cancer; Head and Neck Cancer; Oncology; Squamous Cell Carcinoma
Interventions: Drug: Panitumumab; Drug: Cisplatin
Sponsor: Amgen
Active, not recruiting - verified February 2010
Condition: Advanced Solid Tumors
Intervention: Drug: Epofolate
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: pertuzumab; Drug: Herceptin; Drug: docetaxel
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Condition: Multiple Myeloma
Interventions: Drug: Tanespimycin; Drug: Bortezomib
Sponsor: Bristol-Myers Squibb
Suspended - verified April 2009
Condition: Non-small Cell Lung Cancer
Interventions: Drug: erlotinib [Tarceva]; Drug: Avastin; Drug: Standard platinum-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Advanced Non-Small Cell Lung Cancer
Interventions: Drug: Lapatinib; Drug: Pemetrexed
Sponsor: GlaxoSmithKline
Completed - verified March 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: Endoxana, IMA901, Leukine; Drug: IMA901 and Leukine
Sponsor: immatics Biotechnologies GmbH
Completed - verified February 2010
Condition: Osteosarcoma
Intervention: Drug: pemetrexed
Sponsor: Eli Lilly and Company
Active, not recruiting - verified February 2010
Condition: Pancreatic Neoplasms
Interventions: Drug: KU-0059436 (AZD2281)(PARP inhibitor); Drug: Gemcitabine
Sponsors: AstraZeneca; KuDOS Pharmaceuticals Limited
Active, not recruiting - verified March 2010
Conditions: Ovarian Neoplasms; BRCA1 Protein; BRCA2 Protein
Intervention: Drug: KU-0059436 (AZD2281)(PARP inhibitor)
Sponsors: AstraZeneca; KuDOS Pharmaceuticals Limited
Active, not recruiting - verified March 2010
Condition: Locally Recurrent and Metastatic Breast Cancer
Interventions: Drug: AMG 386 Placebo; Drug: AMG 386; Drug: Bevacizumab; Drug: AMG 386; Drug: AMG 386; Drug: Paclitaxel
Sponsor: Amgen
Active, not recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Biological: Trastuzumab; Drug: Lapatinib
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Tumor Antigen-positive Non-Small Cell Lung Cancer
Interventions: Biological: GSK1572932A Antigen-Specific Cancer Immunotherapeutic; Biological: Placebo Control
Sponsor: GlaxoSmithKline
Recruiting - verified March 2010
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: ABT-263
Sponsors: Abbott; Genentech
Recruiting - verified February 2010
Condition: Carcinoma, Pancreatic Ductal
Interventions: Drug: AG-013736; Drug: Gemcitabine; Drug: Gemcitabine; Drug: placebo
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Renal Cell Carcinoma
Interventions: Drug: Temsirolimus; Drug: Sorafenib
Sponsor: Wyeth
Recruiting - verified February 2010
Condition: Sarcoma, Ewing's
Intervention: Drug: CP-751,871
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Cancer
Interventions: Genetic: polymerase chain reaction; Other: bronchoalveolar lavage; Other: immunoenzyme technique; Other: laboratory biomarker analysis; Procedure: bronchoscopy; Procedure: management of therapy complications
Sponsor: St. Bartholomew's Hospital
Recruiting - verified September 2007
Condition: Recurrent and/or Metastatic Head and Neck Cancer
Interventions: Drug: ARM 1; Drug: ARM 2
Sponsor: Amgen
Active, not recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: AMG 706; Drug: placebo
Sponsors: Amgen; Takeda Global Research & Development Center, Inc.
Recruiting - verified March 2010
Condition: Leukemia, Lymphocytic, Chronic
Intervention: Drug: alvocidib (HMR1275)
Sponsor: Sanofi-Aventis
Recruiting - verified March 2010
Condition: Carcinoma, Non-Small Cell Lung
Interventions: Drug: erlotinib; Drug: sunitinib; Drug: erlotinib; Drug: placebo
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Colorectal Neoplasms
Interventions: Drug: 5 fluorouracil; Drug: irinotecan; Drug: levo- leucovorin; Drug: sunitinib; Drug: 5 fluorouracil; Drug: irinotecan; Drug: levo- leucovorin; Drug: placebo
Sponsor: Pfizer
Completed - verified March 2010
Condition: Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Paclitaxel; Drug: Cyclophosphamide; Drug: Doxorubicin
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified November 2009
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Taxane-based chemotherapy
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Conditions: Lymphoma; Neutropenia; Psychosocial Effects of Cancer and Its Treatment; Small Intestine Cancer; Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: amoxicillin-clavulanate potassium; Drug: ciprofloxacin; Procedure: psychosocial assessment and care; Procedure: quality-of-life assessment
Sponsor: Clatterbridge Centre for Oncology
Recruiting - verified May 2007
Condition: Neoplasms
Intervention: Drug: SU011248
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Neoplasms
Interventions: Drug: Sunitinib + Capecitabine; Drug: Capecitabine
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Conditions: Carcinoma, Renal Cell; Breast Neoplasms; Carcinoma, Islet Cell; Gastrointestinal Stromal Tumors
Intervention: Drug: sunitinib
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Conditions: Non Small Cell Lung Cancer; Lung Cancer
Interventions: Drug: Vandetanib; Drug: Pemetrexed
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Condition: Cancer (Solid Tumors)
Intervention: Drug: BMS-690514
Sponsor: Bristol-Myers Squibb
Recruiting - verified January 2010
Conditions: Neoplasms; Prostatic Neoplasms
Interventions: Drug: cabazitaxel (XRP6258) (RPR116258); Drug: mitoxantrone; Drug: prednisone
Sponsor: Sanofi-Aventis
Completed - verified March 2010
Conditions: Glioma; Medulloblastoma
Interventions: Drug: Irinotecan; Drug: Temozolomide
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Neoplasms
Interventions: Drug: Sunitinib malate; Drug: Taxotere
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: Herceptin; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Recruiting - verified February 2010
Condition: Small Cell Lung Cancer
Interventions: Drug: Amrubicin; Drug: Cisplatin; Drug: Etoposide
Sponsor: Celgene Corporation
Active, not recruiting - verified March 2010
Condition: Colorectal Cancer
Intervention: Drug: pazopanib
Sponsor: GlaxoSmithKline
Completed - verified March 2010
Condition: Thyroid Neoplasms
Intervention: Drug: AG-013736
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Advanced Renal Cell Carcinoma
Intervention: Drug: pazopanib
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Conditions: Colorectal Neoplasms; Melanoma; Prostatic Neoplasms; Renal Cell Carcinoma; Neoplasms
Intervention: Drug: CP-675,206
Sponsor: Pfizer
Recruiting - verified February 2010
Condition: Kidney Neoplasms
Interventions: Drug: Sunitinib malate; Other: Placebo
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: lapatinib
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Condition: Non-small Cell Lung Cancer
Interventions: Drug: Tarceva; Drug: Placebo
Sponsor: OSI Pharmaceuticals
Active, not recruiting - verified October 2009
Condition: Gastrointestinal Stromal Tumor
Interventions: Drug: sunitinib malate; Drug: imatinib mesylate
Sponsor: Pfizer
Terminated - verified March 2010
Condition: Breast Neoplasms
Interventions: Drug: CP-751,871 + exemestane; Drug: exemestane
Sponsors: Pfizer; Massachusetts General Hospital
Recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Ixabepilone; Drug: Ixabepilone; Drug: Bevacizumab; Drug: Bevacizumab; Drug: Paclitaxel; Drug: Bevacizumab
Sponsor: Bristol-Myers Squibb
Completed - verified December 2009
Condition: Metastatic Colorectal Cancer
Interventions: Drug: 5-Fluorouracil, Oxaliplatin, Leucovorin; Drug: 5-Fluorouracil, Oxaliplatin, Leucovorin, Panitumumab
Sponsor: Amgen
Active, not recruiting - verified February 2010
Condition: Non-small Cell Lung Cancer
Intervention: Drug: BMS-275183 (oral taxane)
Sponsor: Bristol-Myers Squibb
Terminated - verified September 2007
Condition: Endocrine Tumors
Interventions: Drug: lanreotide (Autogel formulation); Other: Placebo
Sponsor: Ipsen
Recruiting - verified March 2010
Conditions: Ovarian Cancer; Merkel Cell Carcinoma; SCLC
Intervention: Drug: BB-10901
Sponsor: ImmunoGen, Inc.
Recruiting - verified March 2010
Condition: Metastatic Colorectal Cancer
Interventions: Drug: FOLFIRI; Drug: Panitumumab
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin]; Drug: bevacizumab [Avastin]; Drug: Placebo; Drug: Docetaxel
Sponsor: Hoffmann-La Roche
Active, not recruiting - verified February 2010
Condition: Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma
Interventions: Drug: Zoledronic Acid; Biological: Denosumab
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Non Hodgkin Lymphoma
Interventions: Drug: enzastaurin; Drug: placebo
Sponsor: Eli Lilly and Company
Recruiting - verified March 2010
Condition: Bone Metastases in Men With Hormone-Refractory Prostate Cancer
Interventions: Drug: denosumab; Drug: zoledronic acid
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Bone Metastases in Subjects With Advanced Breast Cancer
Interventions: Biological: Denosumab; Drug: Zoledronic Acid
Sponsors: Amgen; Daiichi Sankyo Inc.
Active, not recruiting - verified March 2010
Condition: Melanoma
Interventions: Drug: Ipilimumab and Dacarbazine; Drug: Placebo and Dacarbazine
Sponsors: Bristol-Myers Squibb; Medarex
Active, not recruiting - verified March 2010
Condition: Metastatic Breast Cancer
Interventions: Drug: Lapatinib; Biological: Trastuzumab
Sponsor: GlaxoSmithKline
Completed - verified March 2010
Condition: Leukemia, Myeloid, Chronic
Interventions: Drug: Dasatinib; Drug: Imatinib
Sponsor: Bristol-Myers Squibb
Completed - verified February 2010
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Docetaxel; Drug: Placebo
Sponsor: AstraZeneca
Completed - verified March 2010
Condition: Prostatic Neoplasms
Interventions: Drug: CP-751,871; Drug: docetaxel; Drug: prednisone; Drug: docetaxel; Drug: prednisone
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Carcinoma, Non-Small-Cell Lung
Interventions: Drug: CP-675,206; Drug: best supportive care
Sponsor: Pfizer
Active, not recruiting - verified February 2010
Condition: Leukemia
Intervention: Drug: Dasatinib
Sponsors: Bristol-Myers Squibb; ITCC
Active, not recruiting - verified March 2010
Condition: Prophylaxis for HPV Infections and Associated Cervical Neoplasia
Interventions: Biological: Cervarix; Biological: Placebo control
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Condition: Ovarian Cancer
Intervention: Drug: CT-2106
Sponsor: Cell Therapeutics
Completed - verified February 2010
Condition: Glioblastoma
Interventions: Drug: enzastaurin; Drug: lomustine
Sponsor: Eli Lilly and Company
Active, not recruiting - verified March 2010
Condition: Hormone Refractory Prostate Cancer
Interventions: Biological: denosumab; Biological: Placebo
Sponsor: Amgen
Active, not recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: pegfilgrastim; Biological: rituximab; Drug: cyclophosphamide; Drug: doxorubicin hydrochloride; Drug: prednisone; Drug: vincristine sulfate; Other: pharmacological study; Radiation: radiation therapy
Sponsor: German High-Grade Non-Hodgkin's Lymphoma Study Group
Recruiting - verified July 2009
Condition: Melanoma
Interventions: Drug: dacarbazine or temozolomide (choice); Drug: CP-675,206
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Refractory Melanoma
Intervention: Drug: CP-675,206
Sponsor: Pfizer
Active, not recruiting - verified February 2010
Condition: Breast Neoplasms
Interventions: Drug: SU011248; Drug: Chemotherapy
Sponsor: Pfizer
Recruiting - verified March 2010
Condition: Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Intervention: Drug: imatinib mesylate
Sponsor: Novartis Pharmaceuticals
Active, not recruiting - verified March 2010
Condition: Philadelphia Positive Chronic Myeloid Leukemia in Accelerated Phase, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Intervention: Drug: imatinib mesylate
Sponsor: Novartis Pharmaceuticals
Active, not recruiting - verified March 2010
Condition: Carcinoma, Renal Cell
Intervention: Drug: sunitinib malate
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Malignant Melanoma
Interventions: Drug: Ipilimumab+ Placebo; Drug: Ipilimumab+ Budesonide
Sponsors: Bristol-Myers Squibb; Medarex
Completed - verified August 2008
Condition: Sarcoma
Interventions: Biological: PEG-interferon alfa-2b; Drug: cisplatin; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: methotrexate
Sponsors: Children's Oncology Group; National Cancer Institute (NCI); University College London Hospitals
Recruiting - verified March 2010
Conditions: Mesothelioma; Lung Cancer
Interventions: Drug: Comparator: Suberoylanilide Hydroxamic Acid (Vorinostat, MK0683); Drug: Comparator: Placebo
Sponsor: Merck
Recruiting - verified March 2010
Condition: Myeloid Leukemia, Chronic, Chronic-Phase
Interventions: Drug: dasatinib; Drug: dasatinib; Drug: dasatinib; Drug: dasatinib
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified January 2009
Conditions: Myeloid Leukemia, Chronic, Accelerated Phase; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Interventions: Drug: dasatinib; Drug: dasatinib; Drug: dasatinib; Drug: dasatinib
Sponsor: Bristol-Myers Squibb
Active, not recruiting - verified September 2009
Conditions: Chronic Myelogenous Leukemia; Acute Lymphoblastic Leukemia (Philadelphia Chromosome Positive); Hypereosinophilic Syndrome; Systemic Mastocytosis
Intervention: Drug: AMN107
Sponsor: Novartis Pharmaceuticals
Active, not recruiting - verified March 2010
Condition: Breast Cancer
Intervention: Drug: lapatinib
Sponsor: GlaxoSmithKline
Completed - verified February 2010
Condition: Chronic Myelogenous Leukemia
Intervention: Drug: Dasatinib
Sponsor: Bristol-Myers Squibb
Completed - verified March 2010
Condition: Non-small Cell Lung Cancer
Intervention: Drug: BMS-275183
Sponsor: Bristol-Myers Squibb
Terminated - verified August 2007
Condition: Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: resveratrol
Sponsors: University of Michigan Cancer Center; National Cancer Institute (NCI)
Completed - verified March 2010
Conditions: Melanoma; Metastases
Interventions: Drug: MDX-010 (anti-CTLA4) monoclonal antibody; Biological: MDX-1379 Melanoma Peptide Vaccine
Sponsor: Bristol-Myers Squibb
Completed - verified March 2010
Condition: Gastrointestinal Neoplasm
Intervention: Drug: SU011248
Sponsor: Pfizer
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: ZD4054; Drug: Placebo
Sponsor: AstraZeneca
Completed - verified February 2010
Condition: Sarcoma
Interventions: Drug: imatinib mesylate; Procedure: conventional surgery
Sponsor: European Organization for Research and Treatment of Cancer
Active, not recruiting - verified November 2006
Conditions: Metastatic Breast Cancer; Advanced Breast Cancer
Interventions: Drug: Letrozole; Drug: Lapatinib (GW572016)
Sponsor: GlaxoSmithKline
Active, not recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Drug: triptorelin; Procedure: oophorectomy; Radiation: radiation therapy
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group; Cancer and Leukemia Group B; NCIC Clinical Trials Group; North Central Cancer Treatment Group; National Surgical Adjuvant Breast and Bowel Project (NSABP); Southwest Oncology Group
Recruiting - verified March 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate
Sponsors: International Breast Cancer Study Group; National Cancer Institute (NCI); Breast International Group
Recruiting - verified March 2010
Conditions: Locally Advanced Breast Cancer; Metastatic Breast Cancer
Interventions: Drug: Fulvestrant; Drug: Exemestane
Sponsor: AstraZeneca
Active, not recruiting - verified March 2010
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Biological: filgrastim; Biological: pegfilgrastim; Drug: ABVD regimen; Drug: BEACOPP regimen; Drug: cyclophosphamide; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: prednisone; Drug: procarbazine hydrochloride; Drug: vinblastine; Drug: vincristine sulfate
Sponsors: European Organization for Research and Treatment of Cancer; Lymphoma Trials Office; Groupe d'Etudes de Lymphomes de L'Adulte; Grup per l'Estudi dels Limfomes de Catalunya i Balears; NCIC Clinical Trials Group; Australasian Leukaemia and Lymphoma Group (ALLG); Nordic Lymphoma Group
Active, not recruiting - verified June 2009
Conditions: Gastrointestinal Stromal Tumor; Sarcoma
Intervention: Drug: brostallicin
Sponsor: European Organization for Research and Treatment of Cancer
Active, not recruiting - verified August 2002
Condition: Breast Neoplasms
Interventions: Drug: Tamoxifen; Drug: Exemestane
Sponsors: Pfizer; International Collaborative Cancer Group (ICCG)
Active, not recruiting - verified February 2010
Condition: Breast Cancer
Interventions: Drug: exemestane; Drug: tamoxifen citrate; Procedure: adjuvant therapy
Sponsor: Cancer Research Campaign Clinical Trials Centre
Active, not recruiting - verified March 2007
Condition: Pancreatic Cancer
Interventions: Drug: erlotinib hydrochloride; Drug: gemcitabine hydrochloride
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Colorectal Cancer
Interventions: Drug: FOLFIRI regimen; Drug: fluorouracil; Drug: irinotecan hydrochloride; Drug: leucovorin calcium
Sponsor: Rhone-Poulenc Rorer
Active, not recruiting - verified December 2009
Condition: Sarcoma
Interventions: Biological: dactinomycin; Drug: busulfan; Drug: doxorubicin hydrochloride; Drug: etoposide; Drug: ifosfamide; Drug: melphalan; Drug: vincristine sulfate; Procedure: autologous hematopoietic stem cell transplantation; Procedure: conventional surgery; Radiation: radiation therapy
Sponsors: University Hospitals, Leicester; National Cancer Institute (NCI); Children's Cancer and Leukaemia Group; Societe Francaise Oncologie Pediatrique; European Organization for Research and Treatment of Cancer; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Germany; Gesellschaft fur Padiatrische Onkologie und Hamatologie - Austria; Swiss Group for Clinical Cancer Research; EBMT Solid Tumors Working Party; Children's Oncology Group
Recruiting - verified March 2010
Conditions: Anemia; Cervical Cancer; Drug/Agent Toxicity by Tissue/Organ; Radiation Toxicity
Interventions: Biological: epoetin alfa; Drug: cisplatin; Procedure: quality-of-life assessment; Radiation: brachytherapy; Radiation: radiation therapy
Sponsors: Gynecologic Oncology Group; National Cancer Institute (NCI); NCIC Clinical Trials Group
Completed - verified May 2004
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: busulfan; Drug: cyclophosphamide; Drug: cyclosporine; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: etoposide; Drug: leucovorin calcium; Drug: mercaptopurine; Drug: methotrexate; Drug: prednisolone; Drug: prednisone; Drug: thioguanine; Drug: vincristine sulfate; Procedure: allogeneic bone marrow transplantation
Sponsor: Dutch Childhood Oncology Group
Active, not recruiting - verified October 2006
Condition: Breast Cancer
Interventions: Procedure: conventional surgery; Radiation: radiation therapy
Sponsor: European Organization for Research and Treatment of Cancer
Recruiting - verified July 2009
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Drug: lurtotecan liposome
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Lung Cancer
Interventions: Drug: carboplatin; Drug: paclitaxel; Drug: rebimastat
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Melanoma (Skin)
Interventions: Biological: pegylated interferon alfa; Procedure: adjuvant therapy
Sponsor: European Organization for Research and Treatment of Cancer
Active, not recruiting - verified October 2000
Conditions: Brain and Central Nervous System Tumors; Breast Cancer; Extragonadal Germ Cell Tumor; Infection; Lung Cancer; Lymphoma; Ovarian Cancer; Small Intestine Cancer; Testicular Germ Cell Tumor; Unspecified Adult Solid Tumor, Protocol Specific
Intervention: Drug: levofloxacin
Sponsor: Cancer Research Campaign Clinical Trials Centre
Active, not recruiting - verified July 2002
Condition: Prostate Cancer
Interventions: Biological: luteinizing hormone-releasing factor; Radiation: radiation therapy
Sponsor: Medical Research Council
Active, not recruiting - verified July 2001
Condition: Head and Neck Cancer
Interventions: Biological: bleomycin sulfate; Drug: fluorouracil; Drug: leucovorin calcium; Drug: methotrexate; Drug: vincristine sulfate; Radiation: low-LET cobalt-60 gamma ray therapy; Radiation: low-LET photon therapy; Radiation: radiation therapy
Sponsor: Cancer Research UK
Active, not recruiting - verified March 2010
Condition: Endometrial Cancer
Interventions: Procedure: adjuvant therapy; Procedure: conventional surgery; Radiation: brachytherapy; Radiation: radiation therapy
Sponsor: Medical Research Council
Active, not recruiting - verified April 1999
Conditions: Fallopian Tube Cancer; Ovarian Cancer; Peritoneal Cavity Cancer
Intervention: Drug: chemotherapy
Sponsors: Medical Research Council; European Organization for Research and Treatment of Cancer
Active, not recruiting - verified September 2005
Condition: Ovarian Cancer
Intervention: Drug: ISIS 5132
Sponsor: NCIC Clinical Trials Group
Completed - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: cyproterone acetate; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: nilutamide; Procedure: orchiectomy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Southwest Oncology Group
Active, not recruiting - verified March 2010
Condition: Prostate Cancer
Interventions: Drug: bicalutamide; Drug: buserelin; Drug: flutamide; Drug: goserelin; Drug: leuprolide acetate; Drug: nilutamide; Procedure: orchiectomy; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; National Cancer Institute (NCI); Eastern Cooperative Oncology Group; Cancer and Leukemia Group B; Southwest Oncology Group; Medical Research Council
Active, not recruiting - verified March 2010
Conditions: Leukemia; Neutropenia
Interventions: Biological: filgrastim; Drug: amsacrine; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: etoposide; Drug: idarubicin; Drug: mitoxantrone hydrochloride; Drug: thioguanine; Drug: tretinoin; Procedure: allogeneic bone marrow transplantation; Procedure: autologous bone marrow transplantation; Procedure: peripheral blood stem cell transplantation; Radiation: radiation therapy
Sponsor: Medical Research Council
Active, not recruiting - verified October 2002
Condition: Leukemia
Interventions: Drug: asparaginase; Drug: cyclophosphamide; Drug: cytarabine; Drug: daunorubicin hydrochloride; Drug: dexamethasone; Drug: doxorubicin hydrochloride; Drug: mercaptopurine; Drug: methotrexate; Drug: pegaspargase; Drug: prednisolone; Drug: thioguanine; Drug: vincristine sulfate; Radiation: radiation therapy
Sponsor: Medical Research Council
Active, not recruiting - verified February 2003
Condition: Lymphoma
Interventions: Biological: bleomycin sulfate; Drug: ABVD regimen; Drug: dacarbazine; Drug: doxorubicin hydrochloride; Drug: vinblastine; Radiation: radiation therapy
Sponsors: NCIC Clinical Trials Group; Eastern Cooperative Oncology Group
Active, not recruiting - verified March 2010
All Categories ... Medical Conditions » ... Cancers » ... United Kingdom 
Login/sign up for more tools for finding clinical trials. Login/Sign up Here
